Potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2). Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC50
values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from the Dana-Farber Cancer Institute.
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Deng et al.
LRRK2 Dephosphorylation increases its ubiquitination.
Zhao et al.
The citations listed below are publications that use Tocris products. Selected citations for LRRK2-IN-1 include:
Showing Results 1 - 3 of 3